Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03418363
Other study ID # OHSU IRB# 17651
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date January 16, 2018
Est. completion date December 11, 2019

Study information

Verified date January 2020
Source Oregon Health and Science University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized study is to learn more about how a supplement called DHEA (dehydroepiandrosterone) affects clotting factors in women taking combined oral contraceptive pills. Current research suggests that the progestin hormone in a specific type of birth control pill may increase a woman's blood clot risk. However, it is unknown exactly how the progestin causes the increased risk. This study aims to learn if taking a daily dose of supplemental androgen (dehydroepiandrosterone, or DHEA) in addition to birth control pills containing DRSP affects proteins related to coagulation.


Description:

While the pro-thrombotic effects of estrogens are well established in women using combined oral contraception (COC), controversy exists over whether the various synthetic progestogens (progestins) used in combination with ethinyl estradiol in COC formulations may modify the risk of venous thromboembolism (VTE). Several studies have demonstrated that different types of progestins used in COCs influence the magnitude of the estrogen-induced changes in coagulation pathway proteins. However, since hepatocytes do not express progesterone receptor, any activity of a progestin must be indirect. While all progestins on the market are strong agonists for the progesterone receptor (PR), most have variable affinity for the androgen receptor (AR), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR). Generations of progestins have been developed, each successive generation exhibiting decreasing levels of androgenicity. Recent epidemiologic studies have suggested an increased risk of VTE in women using low-androgen progestins relative to those using levonorgestrel-containing products. Although no pattern of hepatic globulin changes has been validated as a surrogate marker for thrombosis risk, the overall magnitude of change in various hepatic proteins involved in coagulation is greater with the newer low-androgenic progestins compared to levonorgestrel, leading some experts to suggest that a progestin's androgenic profile may influence the risk of thrombosis. However, a series of well-designed large prospective cohort studies have not confirmed the increased risk of VTE with low-androgen progestins.

A major problem with reconciling the conflicting results from epidemiologic and prospective studies has been the lack of a clear mechanism, as no studies have demonstrated whether these observed changes are mediated through androgen receptor activity. We hypothesize that androgen receptor activity opposes the estrogen receptor-mediated increase in hepatic clotting factors in women using combined oral contraceptives. To test this hypothesis, we propose a randomized clinical trial in which we will enroll healthy women using combined oral contraception containing ethinyl estradiol (EE) with an antiandrogenic progestin (drospirenone, DRSP). Participants will be randomized to treatment with oral androgen (dehydroepiandrosterone, DHEA) or placebo, and we will collect whole blood samples to measure coagulation pathway-related hepatic globulins (APC-r, Protein S, SHBG) before and after treatment.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date December 11, 2019
Est. primary completion date March 11, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 44 Years
Eligibility Inclusion Criteria:

- Women of reproductive age (18-44 years) in generally good health and with body mass index (BMI) between 18 and 35kg/m2

- Premenopausal, with uterus and at least one ovary intact

- Current users (at least 3 months) of combined oral contraception consisting of 0.02 mg (milligram) ethinyl estradiol and 3 mg drospirenone

- Willing to continue use of current combined oral contraception for the next three menstrual cycles

- Have a prescription for combined oral contraception consisting of ethinyl estradiol and drospirenone for the next four cycles

- Not currently using androgen supplementation

- Willing and able to sign the informed consent

- Willing to comply with the study requirements and visit schedule

- No desire to conceive during study participation, approximately 3 months

Exclusion Criteria:

- Currently enrolled in another clinical trial

- Contraindications to androgen supplementation; history of polycystic ovarian syndrome (PCOS)

- Known or suspected pregnancy, pregnancy within 3 months before study enrollment, or desire to conceive during study participation

- Currently breastfeeding

- Known or suspected alcoholism or drug abuse

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
DHEA Oral Capsule
Daily 100mg DHEA supplement
Other:
Placebo Oral Capsule
Daily oral capsule

Locations

Country Name City State
United States Oregon Health & Science University Portland Oregon

Sponsors (1)

Lead Sponsor Collaborator
Oregon Health and Science University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in 3-month plasma levels of APC-r Access change in blood levels from baseline (Visit 1) to study completion visit (Visit 2). Collection of whole blood samples from participants to assess change in levels of APC-r after randomization to DHEA supplementation or placebo for 3 cycles (approximately 3 months). Baseline & Study Completion (month 3)
Primary Change in 3-month plasma levels of protein S Access change in blood levels from baseline (Visit 1) to study completion visit (Visit 2). Collection of whole blood samples from participants to assess change in levels of protein S after randomization to DHEA supplementation or placebo for 3 cycles (approximately 3 months). Baseline & Study Completion (month 3)
Primary Change in 3-month serum levels of SHBG Access change in blood levels from baseline (Visit 1) to study completion visit (Visit 2). Collection of whole blood samples from participants to assess change in levels of SHBG after randomization to DHEA supplementation or placebo for 3 cycles (approximately 3 months). Baseline & Study Completion (month 3)
Primary Change in 3-month serum levels of ethinyl estradiol Access change in blood levels from baseline (Visit 1) to study completion visit (Visit 2). Collection of whole blood samples from participants to assess change in levels of ethinyl estradiol after randomization to DHEA supplementation or placebo for 3 cycles (approximately 3 months). Baseline & Study Completion (month 3)
Primary Change in 3-month serum levels of DHEA Access change in blood levels from baseline (Visit 1) to study completion visit (Visit 2). Collection of whole blood samples from participants to assess change in levels of DHEA after randomization to DHEA supplementation or placebo for 3 cycles (approximately 3 months). Baseline & Study Completion (month 3)
Primary Change in 3-month serum levels of free and total testosterone Access change in blood levels from baseline (Visit 1) to study completion visit (Visit 2). Collection of whole blood samples from participants to assess change in levels of total testosterone and free testosterone (calculated using serum albumin) after randomization to DHEA supplementation or placebo for 3 cycles (approximately 3 months). Baseline & Study Completion (month 3)
See also
  Status Clinical Trial Phase
Completed NCT03279120 - Safety, PK, and PD Study of IVRs Releasing TFV and LNG Phase 1
Withdrawn NCT03725358 - A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon. N/A
Completed NCT01170390 - Oral Contraceptives and Body Mass Index Phase 4
Recruiting NCT05932537 - Ablation of Subcutaneous Contraceptive Implants in the Operating Room
Withdrawn NCT04882137 - Barriers to Referring Adolescent Women for Etonogestrel Implant. N/A
Completed NCT02613039 - Oral Contraceptive Therapy and Sexuality Phase 4
Completed NCT01425060 - Improving Effective Contraceptive Use Among Opioid-maintained Women Phase 1
Completed NCT03626597 - Community-based Provision of Urine Pregnancy Tests as Linkage to Reproductive Health Services N/A
Recruiting NCT04558229 - RCT Evaluating Standardized Counseling on Early Discontinuation for Irregular Bleeding in Nexplanon Users Phase 4
Recruiting NCT05644886 - Pilot Study on Engaging Family Physicians in Family Planning in Pakistan N/A
Completed NCT03253783 - The Evaluation of Pulse: A Mobile Health App and Teen Pregnancy Prevention Program N/A
Completed NCT03571932 - Assessment of Family Planning and Immunization Service Integration in Liberia
Completed NCT04043130 - The Evaluation of Pulse: A Mobile Health App and Teen Pregnancy Prevention Program N/A
Completed NCT03336346 - Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana
Active, not recruiting NCT03984695 - Sexual Health Empowerment for Women's Health N/A
Completed NCT02411357 - Improving Effective Contraceptive Use Among Opioid-maintained Women: Stage II N/A
Completed NCT05806463 - Efficacy of Mother's Time in Ethiopia N/A
Recruiting NCT05328648 - Randomized Controlled Trial to Address Unintended Pregnancy Rates in Low Resource Settings N/A
Active, not recruiting NCT05061472 - A 6-month Observational Study on Combined Oral Contraceptives and Body Weight in Pre-Menopausal Women With Overweight or Obesity
Not yet recruiting NCT05988983 - The Over The Counter Pill National Study